Financials in USD. Standardized financial statements.
A compact view of how Xeris Biopharma Holdings, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $291.85M | $203.07M | $163.91M | $110.25M | $49.59M | $20.43M | $2.72M | $2.46M | $1.56M | $1.07M |
| Revenue Growth? | +43.7% | +23.9% | +48.7% | +122.3% | +142.7% | +650.7% | +10.4% | +58.4% | +44.7% | 0.0% |
| Cost of Revenue? | $53.41M | $36.83M | $28.64M | $22.63M | $13.32M | $9.33M | $1.60M | $42,000 | $4,000 | $8,000 |
| Gross Profit? | $238.43M | $166.24M | $135.27M | $87.61M | $36.27M | $11.11M | $1.12M | $2.42M | $1.55M | $1.07M |
| Gross Margin? | +81.7% | +81.9% | +82.5% | +79.5% | +73.1% | +54.4% | +41.1% | +98.3% | +99.7% | +99.3% |
| Operating Expenses? | $213.54M | $199.88M | $179.28M | $169.55M | $151.43M | $94.65M | $123.50M | $61.77M | $28.18M | $14.30M |
| Operating Income? | $24.90M | -$33.65M | -$44.01M | -$81.94M | -$115.16M | -$83.55M | -$122.38M | -$59.34M | -$26.63M | -$13.23M |
| EBITDA? | $12.71M | -$13.99M | -$23.73M | -$69.31M | -$113.67M | -$79.12M | -$117.80M | -$57.22M | -$26.38M | -$13.09M |
| Income Before Tax | $554,000 | -$57.10M | -$63.50M | -$96.08M | -$122.72M | -$91.25M | -$126.04M | -$60.08M | -$26.55M | -$13.21M |
| Income Tax Expense | $0 | -$2.27M | -$1.25M | -$1.42M | $0 | -$110,000 | -$458,000 | $0 | $1,000 | -$3,000 |
| Net Income? | $554,000 | -$54.84M | -$62.26M | -$94.66M | -$122.72M | -$91.14M | -$125.58M | -$60.08M | -$26.55M | -$13.21M |
| EPS? | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 | $-2.14 | $-3.49 | $-4.99 | $-13.09 | $-7.17 |
| Diluted EPS? | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 | $-2.14 | $-3.49 | $-4.99 | $-13.09 | $-7.17 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality